CYP3A5 Genotype had no impact on intrapatient variability of tacrolimus clearance in renal transplant recipients

Therapeutic Drug Monitoring

Volumn 35, Issue 3, 2013, Pages 328-331

  Spierings, N ^a   Holt, D W ^a   MacPhee, Iain A M ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

CYP3A5; Kidney transplantation; Pharmacogenetics; Tacrolimus

Indexed keywords

CYTOCHROME P450 3A5; TACROLIMUS;

ADULT; ARTICLE; DRUG CLEARANCE; ETHNICITY; FEMALE; GENE EXPRESSION; GENOTYPE; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; KIDNEY FUNCTION; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PHARMACOGENETICS; RETROSPECTIVE STUDIES; TACROLIMUS; TIME FACTORS;

EID: 84880081676     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318289644d     Document Type: Article

References (13)

1. Borra LCP, Roodnat JI, Kal JA, et al. High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrol Dial Transplant. 2010;25:2757-2763.
2. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27:383-391. (Pubitemid 32268418)
3. MacPhee IAM, Fredericks S, Tai T, et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. Transplantation. 2001; 74:1486.
4. MacPhee IAM, Fredericks S, Mohamed M, et al. Tacrolimus pharmacogenetics: the CYP3A51 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. Transplantation. 2005;79:499-502. (Pubitemid 40280186)
5. MacPhee IAM, Fredericks S, Tai T, et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant. 2004;4:914-919. (Pubitemid 38745590)
6. Thervet E, LoriotMA, Barbier S, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther. 2010;87:721-726.
7. Yong Chung J, Jung Lee Y, Bok Jang S, et al. CYP3A53 genotype associated with intrasubject pharmacokinetic variation toward tacrolimus in bioequivalence study. Ther Drug Monit. 2010;32: 67-72.
8. Pashaee N, Bouamar R, Hesselink DA, et al. CYP3A5 genotype is not related to the intrapatient variability of tacrolimus clearance. Ther Drug Monit. 2011;33:369-371.
9. Van Schaik RH, van der Heiden IP, van den Anker JN, et al. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem. 2002;48: 1668-1671.
10. Hustert E, Haberl M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics. 2001;11:773-779. (Pubitemid 33151512)
11. MacPhee IA, Holt DW. A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype. Transplantation. 2008;85:163-165. (Pubitemid 351156844)
12. Ng FL, Holt DW, Chang RWS, et al. Black renal transplant recipients have poorer graft survival than CYP3A5 expressers from other ethnic groups. Nephrol Dial Transplant. 2009;25:628-634.
13. Barry A, Levine M. A systematic review of the effect of CYP3A5 genotype on the apparent oral clearance of tacrolimus in renal transplant recipients. Ther Drug Monit. 2010;32:708-714.